Products The inhaled human insulin Exubera (Pfizer, powder inhalation) is no longer commercially available. It was withdrawn from the market in 2007 for commercial reasons. In 2014, a new product was approved in the United States; see Inhalable Insulin. Structure and properties Human insulin (C257H383N65O77S6, Mr = 5808 g/mol) is a polypeptide with the structure … Exubera
Products Sitaxentan had been on the market in the EU since 2006 in the form of film-coated tablets (Thelin 100 mg, Pfizer). It was withdrawn from the market in 2010 because of liver-toxic side effects. Structure and properties Sitaxentan (C18H15ClN2O6S2, Mr = 454.9 g/mol) is an oxazole, thiophene, benzodioxole, and sulfonamide derivative. It is present … Sitaxentan
Products Sofosbuvir is commercially available in the form of film-coated tablets (Sovaldi). It was approved in the United States and EU in 2013 and in many countries in 2014. The very high price of the drug has been a source of debate. Sofosbuvir is also combined fixed with ledipasvir (Harvoni). Cheaper generics are available in … Sofosbuvir
Products Saxagliptin is commercially available in the form of film-coated tablets (Onglyza). It was approved in many countries after sitagliptin (Januvia) and vildagliptin (Galvus) as the 3rd active ingredient from the gliptins group in February 2010. Since 2012, two additional combination products with metformin have been registered (Duoglyze, Kombiglyze XR). Kombiglyze XR entered the market … Saxagliptin
Products and withdrawal from the market Sibutramine was approved in 1999 and was commercially available in many countries in 10- and 15-mg capsule form (Reductil, Abbott AG). On March 29, 2010, Abbott AG, in consultation with Swissmedic, informed the public that the marketing authorization had been suspended. Since then, sibutramine may no longer be prescribed … Sibutramine
Products In many countries, there are no drugs containing carisoprodol on the market. In other countries, it is available in tablet form (Soma, Somadril). It has been approved in the United States since 1959. In 2007, the European Medicines Agency concluded that the benefits of the drug did not outweigh the risks. Structure and properties … Carisoprodol
Products Caffeine citrate solution was newly approved in many countries in 2016 (Peyona). It was available earlier in other countries. Structure and properties Caffeine (C8H10N4O2, Mr = 194.2 g/mol) exists as a white crystalline powder or as white silk-like crystals and is sparingly soluble in water. The substance sublimes readily. Citric acid monohydrate (C6H8O7 – … Caffeine Citrate Solution
Symptoms Possible symptoms of multiple sclerosis include: Weakness, numbness of the extremities. Visual disturbances, eye pain, optic neuritis. Paresthesias (eg, formication, tingling), pain, nerve pain. Tremor, coordination / balance disorders. Speech and swallowing disorders Dizziness, lightheadedness Fatigue Urinary incontinence, constipation Sexual function disorders, erectile dysfunction The disease is often relapsing and recurrent (relapsing-remitting multiple sclerosis), … Multiple Sclerosis Causes and Treatment
Products Eculizumab is commercially available as a concentrate for the preparation of an infusion solution (Soliris). It was approved in many countries in January 2010. Structure and Properties Eculizumab is a monoclonal antibody produced by recombinant DNA technology in NSO cell lines. It is composed of two heavy and two light chains of amino acids … Eculizumab
Products Lixisenatide was approved as a subcutaneous solution for injection in the EU in 2012, in the United States in 2016, and in many countries in 2017 (Lyxumia). Lixisenatide is also combined with insulin glargine; see iGlarLixi (Suliqua). Structure and properties Lixisenatide is a peptide and GLP1 analog of 44 amino acids that, like exenatide, … Lixisenatide
Products Tramadol is commercially available in the form of tablets, capsules, melting tablets, drops, effervescent tablets, suppositories, and as a solution for injection. (Tramal, generic). Fixed combinations with acetaminophen are also available (Zaldiar, generic). Tramadol was developed by Grünenthal in Germany in 1962 and has been approved in many countries since 1977 and in the … Tramadol: Drug Effects, Side Effects, Dosage and Uses
Products Liraglutide was approved in many countries in 2009 as a solution for injection in a prefilled pen (Victoza). In 2014, a fixed-dose combination with insulin degludec was released (Xultophy); see IDegLira. In 2016, Saxenda was registered for the treatment of overweight and obesity. Its related successor, semaglutide, unlike liraglutide, only needs to be injected … Liraglutide
